Ontak gains full US approval for CD25-positive cutaneous T-cell lymphoma
This article was originally published in Scrip
Eisaihas received full US FDAapproval for its fusion protein Ontak (denileukin diftitox) for the orphan indication of persistent or recurrent CD25-positive cutaneous T-cell lymphoma (CTCL), following a Phase III trial which confirmed response rate benefits in such patients.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.